DTx in 2024: Where Are We With Business and Reimbursement Models? (Andy Molnar)
In the last few years, we’ve witnessed a whirlwind of developments in the world of Digital Therapeutics (DTx) – from FDA approvals sparking optimism for the industry, to the establishment of regulatory frameworks in countries like Germany, France, and Belgium.
However, in 2023, the industry faced a stark reality check, marked by the fall of some key players and healthcare systems’ hesitancy towards embracing and financing these innovations. This turbulence has reshaped strategies and raised critical questions about the future of DTx.
🔍 In this episode learn more about:
📊 The current state of the DTx industry in 2024,
🗣️ Key debates of digital therapies industry players,
🌐 Advocacy efforts pushing the boundaries for global adoption,
🚀 Strategies to accelerate the integration of digital therapies worldwide.
Newsletter: fodh.substack.com
Website: www.facesofdigitalhealth.com
